Form 4: Zomedica SVP Buys 150,000 Shares

Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, purchased 150,000 shares of common stock at $0.097 per share.

Summary

• Russell Kevin Klass, Senior Vice President of Sales at Zomedica Corp., acquired 150,000 shares of common stock.
• The transaction occurred on November 13, 2025, at a price of $0.097 per share.
• Following this purchase, Mr. Klass directly beneficially owns 5,784,101 shares of Zomedica Corp. common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The insider purchase by a senior executive is a positive signal, indicating confidence in the company's prospects. The transaction amount, while not massive, is significant enough to warrant attention. The Rule 10b5-1 plan suggests a pre-planned, rather than opportunistic, purchase, which can be viewed neutrally to positively.

Positives

• An insider, the Senior Vice President of Sales, purchased a significant number of shares (150,000 shares), indicating confidence in the company's future prospects.
• The purchase was made at $0.097 per share, suggesting management believes the stock is undervalued at this price point.

Future Outlook

This Form 4 filing does not contain any explicit forward-looking statements or guidance.

Industry Context

Insider buying, especially from a senior sales executive, can be interpreted as a positive signal within the animal health and diagnostics industry, suggesting internal confidence in Zomedica's product pipeline or market strategy. While a single transaction, it aligns with a broader trend where management's alignment with shareholder interests is viewed favorably.

Comparison to Industry Standards

• This filing reports an individual insider transaction and does not provide sufficient data for a direct comparison to industry-wide financial benchmarks or specific competitor results.
• However, insider purchases are generally viewed positively across all industries as a sign of management's belief in the company's future.

Related Party Transactions

• Russell Kevin Klass, a Senior Vice President of Zomedica Corp., purchased 150,000 shares of the company's common stock, which constitutes a related party transaction as it involves an insider acquiring company securities.

Stakeholder Impact

• Shareholders: Potentially positive, as insider buying often signals management's belief in future stock appreciation, which could boost investor confidence.
• Employees: May view the executive's purchase as a sign of stability and positive outlook for the company.

Key Dates

Recommendation

While insider buying is generally a positive indicator, a single transaction, even by a senior executive, typically warrants a 'hold' recommendation rather than a 'buy' unless accompanied by other strong positive catalysts or a significant undervaluation. The purchase at $0.097 per share suggests the insider sees value, but without broader financial context or strategic updates, a more aggressive recommendation is not justified based solely on this Form 4.

Keywords

Zomedica Corp, ZOMDF, Insider Trading, Form 4, Stock Purchase, Russell Kevin Klass, Senior Vice President Sales, Equity Acquisition, Rule 10b5-1